Losartan improves renal function and pathology in obese ZSF-1 rats

Area of Science:

• Nephrology
• Pharmacology
• Diabetology

Background:

• Diabetic nephropathy (DN) is a common complication of diabetes.
• Losartan, an angiotensin II type I receptor blocker, is a standard treatment for DN.
• Obese ZSF-1 rats model human Type II DN, making them suitable for studying DN progression and treatment.

Purpose of the Study:

• To investigate the renoprotective effects of losartan in obese ZSF-1 rats with DN.
• To evaluate how the timing of losartan administration impacts its efficacy in treating DN.

Main Methods:

• Obese ZSF-1 rats underwent uninephrectomy or sham surgery.
• Losartan was administered at doses of 3, 10, or 30 mg/kg, starting either 3 or 9 weeks post-surgery.
• Treatment duration was 12 weeks, with assessments of proteinuria, lipids, glomerular filtration rate (GFR), tubulointerstitial fibrosis, and urinary biomarkers.

Main Results:

• Losartan dose-dependently reduced urinary protein and blood lipids.
• Earlier losartan treatment showed greater efficacy in preserving GFR and reducing tubulointerstitial fibrosis, even at the lowest dose.
• Specific urinary biomarkers (sTNFR1, TIMP-1, L-FABP, KIM-1) were decreased by losartan.

Conclusions:

• Losartan demonstrated renoprotective effects in ZSF-1 rats with DN, improving pathological and functional outcomes.
• Early initiation of losartan treatment is crucial for preventing GFR decline and mitigating fibrosis development in DN.
• The study underscores the significance of early intervention in managing diabetic nephropathy.